Zeltia changes name of subsid to Noscira

28 September 2008

Spain's Zeltia group has decided to change the name of its Neuropharma subsidiary to Noscira in order to help the company work towards a stock exchange listing.

The affiliate is engaged in the discovery and development of marine-based drugs for the treatment of central nervous system diseases. Belen Sopesen, Noscira's director general, says clinical trials of an Alzheimer's drug are to be launched and talks are in hand with several drug majors over potential licensing outside Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight